Frazier Life Sciences Management, L.P.
Source: SEC Form 13F · as of Mar 2026Frazier Life Sciences Management, L.P. holds 14 biotech & pharma companies tracked by BioSniper, totaling $1.75B in value as of Mar 2026 (SEC Form 13F).
Companies held
14
Total value held
$1.75B
BioSniper AIPage evidence connected
Prepared research question
What matters most for NEWAMSTERDAM PHARMA CO N.V. (NAMS)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| NAMSNEWAMSTERDAM PHARMA CO N.V. | 16,943,774 | $542.4M |
| BBIOBridgeBio Pharma, Inc. | 3,448,139 | $256.1M |
| ARQTArcutis Biotherapeutics, Inc. | 9,874,511 | $232.6M |
| MAZEMaze Therapeutics, Inc. | 4,567,274 | $136.3M |
| PVLAPALVELLA THERAPEUTICS, INC. | 882,400 | $110.0M |
| KALVKalVista Pharmaceuticals, Inc. | 4,961,108 | $99.9M |
| IRONDisc Medicine, Inc. | 1,354,852 | $86.6M |
| CYTKCYTOKINETICS INC | 1,159,879 | $76.4M |
| RVMDREVOLUTION MEDICINES, INC. | 675,686 | $65.7M |
| SVRASavara Inc | 9,720,852 | $53.1M |
| AGIOAGIOS PHARMACEUTICALS, INC. | 1,256,080 | $42.5M |
| ACADACADIA PHARMACEUTICALS INC | 1,438,198 | $32.0M |
| IMCRImmunocore Holdings plc | 484,782 | $14.6M |
| AUTLAutolus Therapeutics plc | 4,447,910 | $6.1M |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.